Validated procedure for simultaneous trace level determination of the anti-cancer agent gemcitabine and its metabolite in human urine by high-performance liquid chromatography with tandem mass spectrometry

Cristina Sottani, Massimo Zucchetti, Marco Zaffaroni, Maurizio Bettinelli, Claudio Minoia

Research output: Contribution to journalArticle

24 Citations (Scopus)

Abstract

A sensitive, accurate and reproducible procedure has been developed for the quantitative determination of gemcitabine (2′,2′ -difluorodeoxycytidine, dFdC) and its metabolite 2′,2′ -difluorodeoxyuridine (2dFdU) in human urine. The samples (2 mL) were extracted by solid-phase extraction (SPE) and analyzed by reversed-phase high-performance liquid chromatography coupled with tandem mass spectrometry (HPLC/MS/MS), operating in multiple reaction monitoring (MRM mode). This procedure was validated using 2′-deoxycytidine as internal standard (IS). The urine assay was linear over the range 0-50 μg/L, with a limit of quantification (LLOQ) of 0.2 μg/L for gemcitabine and 1.0 μg/L for the metabolite. The respective limits of detection (LODs) for dFdC and 2dFdU were 0.05 and 0.3 μg/L. The precision and accuracy of the assay were determined on three different days. The within-series precision was found to be always less than 8. 5 and 12.7% for gemcitabine and 2dFdU, respectively. The overall precision expressed as relative standard deviation (CVr) was always less than 7.1% for both analytes. The recovery of gemcitabine was always greater than 90% with a CVr

Original languageEnglish
Pages (from-to)1017-1023
Number of pages7
JournalRapid Communications in Mass Spectrometry
Volume18
Issue number10
Publication statusPublished - 2004

Fingerprint

gemcitabine
High performance liquid chromatography
Metabolites
Mass spectrometry
Assays
Deoxycytidine
Recovery
Monitoring

ASJC Scopus subject areas

  • Analytical Chemistry
  • Spectroscopy

Cite this

@article{4dff31257be944549e9f608f98d5c603,
title = "Validated procedure for simultaneous trace level determination of the anti-cancer agent gemcitabine and its metabolite in human urine by high-performance liquid chromatography with tandem mass spectrometry",
abstract = "A sensitive, accurate and reproducible procedure has been developed for the quantitative determination of gemcitabine (2′,2′ -difluorodeoxycytidine, dFdC) and its metabolite 2′,2′ -difluorodeoxyuridine (2dFdU) in human urine. The samples (2 mL) were extracted by solid-phase extraction (SPE) and analyzed by reversed-phase high-performance liquid chromatography coupled with tandem mass spectrometry (HPLC/MS/MS), operating in multiple reaction monitoring (MRM mode). This procedure was validated using 2′-deoxycytidine as internal standard (IS). The urine assay was linear over the range 0-50 μg/L, with a limit of quantification (LLOQ) of 0.2 μg/L for gemcitabine and 1.0 μg/L for the metabolite. The respective limits of detection (LODs) for dFdC and 2dFdU were 0.05 and 0.3 μg/L. The precision and accuracy of the assay were determined on three different days. The within-series precision was found to be always less than 8. 5 and 12.7{\%} for gemcitabine and 2dFdU, respectively. The overall precision expressed as relative standard deviation (CVr) was always less than 7.1{\%} for both analytes. The recovery of gemcitabine was always greater than 90{\%} with a CVr",
author = "Cristina Sottani and Massimo Zucchetti and Marco Zaffaroni and Maurizio Bettinelli and Claudio Minoia",
year = "2004",
language = "English",
volume = "18",
pages = "1017--1023",
journal = "Rapid Communications in Mass Spectrometry",
issn = "0951-4198",
publisher = "John Wiley and Sons Ltd",
number = "10",

}

TY - JOUR

T1 - Validated procedure for simultaneous trace level determination of the anti-cancer agent gemcitabine and its metabolite in human urine by high-performance liquid chromatography with tandem mass spectrometry

AU - Sottani, Cristina

AU - Zucchetti, Massimo

AU - Zaffaroni, Marco

AU - Bettinelli, Maurizio

AU - Minoia, Claudio

PY - 2004

Y1 - 2004

N2 - A sensitive, accurate and reproducible procedure has been developed for the quantitative determination of gemcitabine (2′,2′ -difluorodeoxycytidine, dFdC) and its metabolite 2′,2′ -difluorodeoxyuridine (2dFdU) in human urine. The samples (2 mL) were extracted by solid-phase extraction (SPE) and analyzed by reversed-phase high-performance liquid chromatography coupled with tandem mass spectrometry (HPLC/MS/MS), operating in multiple reaction monitoring (MRM mode). This procedure was validated using 2′-deoxycytidine as internal standard (IS). The urine assay was linear over the range 0-50 μg/L, with a limit of quantification (LLOQ) of 0.2 μg/L for gemcitabine and 1.0 μg/L for the metabolite. The respective limits of detection (LODs) for dFdC and 2dFdU were 0.05 and 0.3 μg/L. The precision and accuracy of the assay were determined on three different days. The within-series precision was found to be always less than 8. 5 and 12.7% for gemcitabine and 2dFdU, respectively. The overall precision expressed as relative standard deviation (CVr) was always less than 7.1% for both analytes. The recovery of gemcitabine was always greater than 90% with a CVr

AB - A sensitive, accurate and reproducible procedure has been developed for the quantitative determination of gemcitabine (2′,2′ -difluorodeoxycytidine, dFdC) and its metabolite 2′,2′ -difluorodeoxyuridine (2dFdU) in human urine. The samples (2 mL) were extracted by solid-phase extraction (SPE) and analyzed by reversed-phase high-performance liquid chromatography coupled with tandem mass spectrometry (HPLC/MS/MS), operating in multiple reaction monitoring (MRM mode). This procedure was validated using 2′-deoxycytidine as internal standard (IS). The urine assay was linear over the range 0-50 μg/L, with a limit of quantification (LLOQ) of 0.2 μg/L for gemcitabine and 1.0 μg/L for the metabolite. The respective limits of detection (LODs) for dFdC and 2dFdU were 0.05 and 0.3 μg/L. The precision and accuracy of the assay were determined on three different days. The within-series precision was found to be always less than 8. 5 and 12.7% for gemcitabine and 2dFdU, respectively. The overall precision expressed as relative standard deviation (CVr) was always less than 7.1% for both analytes. The recovery of gemcitabine was always greater than 90% with a CVr

UR - http://www.scopus.com/inward/record.url?scp=2542457707&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=2542457707&partnerID=8YFLogxK

M3 - Article

C2 - 15150823

AN - SCOPUS:2542457707

VL - 18

SP - 1017

EP - 1023

JO - Rapid Communications in Mass Spectrometry

JF - Rapid Communications in Mass Spectrometry

SN - 0951-4198

IS - 10

ER -